Dermatofibrosarcoma protuberans: A comprehensive review and update on diagnosis and management

Seminars in Diagnostic Pathology

Volumn 30, Issue 1, 2013, Pages 13-28

  Llombart, Beatriz ^a   Serra Guillén, Carlos ^a   Monteagudo, Carlos ^b   López Guerrero, José Antonio ^a   Sanmartín, Onofre ^a  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR B; PROTEIN P53;

ADVANCED CANCER; ALPHA CHAIN TYPE 1 OF COLLAGEN GENE; ARTICLE; ATROPHIC DERMATOFIBROSARCOMA PROTUBERANS; BEDNAR TUMOR; BONE MARROW SUPPRESSION; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CHEMOSURGERY; CHEMOTHERAPY INDUCED EMESIS; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 22; DERMATOFIBROSARCOMA PROTUBERANS; DIFFERENTIAL DIAGNOSIS; DISTANT METASTASIS; DYSPEPSIA; FIBROSARCOMATOUS DERMATOFIBROSARCOMA PROTUBERANS; GENE; GENE FUSION; GIANT CELL FIBROBLASTOMA; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; MYOID DERMATOFIBROSARCOMA PROTUBERANS; MYXOID DERMATOFIBROSARCOMA PROTUBERANS; NAUSEA; PLATELET DERIVED GROWTH FACTOR BETA GENE; PRIORITY JOURNAL; SCLEROSING DERMATOFIBROSARCOMA PROTUBERANS; TUMOR DIAGNOSIS; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR REGRESSION; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DERMATOFIBROSARCOMA; HUMANS; MOHS SURGERY; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PYRIMIDINES; SKIN NEOPLASMS; TRANSLOCATION, GENETIC;

EID: 84872372283     PISSN: 07402570     EISSN: 19301111     Source Type: Journal    
DOI: 10.1053/j.semdp.2012.01.002     Document Type: Article

References (168)

1. Gloster H.M. Dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996, 35:355-374. quiz:75-76.
2. Sanmartín O., Llombart B., López-Guerrero J.A., et al. [Dermatofibrosarcoma protuberans]. Actas Dermosifiliogr 2007, 98:77-87.
3. Sherwell S. Morphea. Arch Dermatol 1890, 8:72-73.
4. Taylor R.W. Sarcomatous tumors resembling in some respects keloids. Arch Dermatol 1890, 8:384-387.
5. Darier J., Ferrand M. Dermatofibromes progressifs et récidivants ou fibrosarcomes de la peu. Ann Dermatol Syph 1924, 5:545-562.
6. Hoffman E. Ueber das knollentribende fibrosarkam der haut (dermatofibrosarcoma protuberans). Dermatol Z 1925, 43:1-28.
7. Taylor H.B., Helwig E.B. Dermatofibrosarcoma protuberans. A study of 115 cases. Cancer 1962, 15:717-725.
8. Altman D.A., Nickoloff B.J., Fivenson D.P. Differential expression of factor XIIIa and CD34 in cutaneous mesenchymal tumors. J Cutan Pathol 1993, 20:154-158.
9. Kutzner H. Expression of the human progenitor cell antigen CD34 (HPCA-1) distinguishes dermatofibrosarcoma protuberans from fibrous histiocytoma in formalin-fixed, paraffin-embedded tissue. J Am Acad Dermatol 1993, 28:613-617.
10. Abenoza P., Lillemoe T. CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans. Am J Dermatopathol 1993, 15:429-434.
11. Cohen P.R., Rapin R.P., Farhood A.I. Dermatofibroma and dermatofibrosarcoma protuberans: differential expression of CD34 and factor XIIIa. Am J Dermatopathol 1994, 16:573-574.
12. Kahn H.J., Fekete E., From L. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa. Hum Pathol 2001, 32:50-56.
13. Bridge J.A., Neff J.R., Sandberg A.A. Cytogenetic analysis of dermatofibrosarcoma protuberans. Cancer Genet Cytogenet 1990, 49:199-202.
14. Mandahl N., Heim S., Willén H., et al. Supernumerary ring chromosome as the sole cytogenetic abnormality in a dermatofibrosarcoma protuberans. Cancer Genet Cytogenet 1990, 49:273-275.
15. Pedeutour F., Simon M.P., Minoletti F., et al. Ring 22 chromosomes in dermatofibrosarcoma protuberans are low-level amplifiers of chromosome 17 and 22 sequences. Cancer Res 1995, 55:2400-2403.
16. Minoletti F., Miozzo M., Pedeutour F., et al. Involvement of chromosomes 17 and 22 in dermatofibrosarcoma protuberans. Genes Chromosomes Cancer 1995, 13:62-65.
17. Naeem R., Lux M.L., Huang S.F., et al. Ring chromosomes in dermatofibrosarcoma protuberans are composed of interspersed sequences from chromosomes 17 and 22. Am J Pathol 1995, 147:1553-1558.
18. Mandahl N., Limon J., Mertens F., et al. Ring marker containing 17q and chromosome 22 in a case of dermatofibrosarcoma protuberans. Cancer Genet Cytogenet 1996, 89:88-91.
19. Bendix-Hansen K., Myhre-Jensen O., Kaae S. Dermatofibrosarcoma protuberans. A clinico-pathological study of nineteen cases and review of world literature. Scand J Plast Reconstr Surg 1983, 17:247-252.
20. Chuang T.Y., Su W.P., Muller S.A. Incidence of cutaneous T cell lymphoma and other rare skin cancers in a defined population. J Am Acad Dermatol 1990, 23:254-256.
21. Criscione V.D., Weinstock M.A. Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol 2007, 56:968-973.
22. Martin L., Combemale P., Dupin M., et al. The atrophic variant of dermatofibrosarcoma protuberans in childhood: a report of six cases. Br J Dermatol 1998, 139:719-725.
23. Llombart B., Sanmartin O., López-Guerrero J.A. Dermatofibrosarcoma protuberante en la infancia. Piel 2006, 21:435-441.
24. Martin L., Piette F., Blanc P., et al. Clinical variants of the preprotuberant stage of dermatofibrosarcoma protuberans. Br J Dermatol 2005, 153:932-936.
25. Strauss R.M., Merchant W.J., Roberts P., et al. A case of childhood dermatofibrosarcoma protuberans without detected cytogenetic abnormality. Br J Dermatol 2003, 148:1051-1055.
26. Pack G.T., Tabah E.J. Dermato-fibrosarcoma protuberans. A report of 39 cases. AMA Arch Surg 1951, 62:391-411.
27. Rutgers E.J., Kroon B.B., Albus-Lutter C.E., et al. Dermatofibrosarcoma protuberans: treatment and prognosis. Eur J Surg Oncol 1992, 18:241-248.
28. Tan A.W., Tan S.H. Dermatofibrosarcoma protuberans: a clinicopathological analysis of 10 cases in Asians. Australas J Dermatol 2004, 45:29-33.
29. Serra-Guillen C., Sanmartin O., Llombart B., et al. Correlation between preoperative magnetic resonance imaging and surgical margins with modified Mohs for dermatofibrosarcoma protuberans. Dermatol Surg 2011, 37:1638-1645.
30. Rabinowitz L.G., Luchetti M.E., Segura A.D., et al. Acrally occurring dermatofibrosarcoma protuberans in children and adults. J Dermatol Surg Oncol 1994, 20:655-659.
31. McPeak C.J., Cruz T., Nicastri A.D. Dermatofibrosarcoma protuberans: an analysis of 86 cases-five with metastasis. Ann Surg 1967, 166:803-816.
32. Petoin D.S., Baruch J., Raulo Y., et al. Darier-Ferrand progressive and recurrent dermatofibroma. Anatomo-clinical study of 17 cases]. Ann Chir Plast Esthet 1985, 30:338-344.
33. McLoughlin P.M., Girach M., Wood G.A. Dermatofibrosarcoma protuberans of the scalp. Br J Oral Maxillofac Surg 1992, 30:401-403.
34. McLelland J., Chu T. Dermatofibrosarcoma protuberans arising in a BCG vaccination scar. Arch Dermatol 1988, 124:496-497.
35. Bukhari I., Al Akloby O., Bedaiwi Y. Dermatofibrosarcoma protuberans at the site of a central venous line. Case report. Am J Clin Dermatol 2005, 6:61-64.
36. Laskin W.B. Dermatofibrosarcoma protuberans. CA Cancer J Clin 1992, 42:116-125.
37. Lambert W.C., Abramovits W., Gonzalez-Sevra A., et al. Dermatofibrosarcoma non-protuberans: description and report of five cases of a morpheaform variant of dermatofibrosarcoma. J Surg Oncol 1985, 28:7-11.
38. Barnes L., Coleman J.A., Johnson J.T. Dermatofibrosarcoma protuberans of the head and neck. Arch Otolaryngol 1984, 110:398-404.
39. Rockley P.F., Robinson J.K., Magid M., et al. Dermatofibrosarcoma protuberans of the scalp: a series of cases. J Am Acad Dermatol 1989, 21:278-283.
40. Rich J.D., Zbylski J.R., LaRossa D.D. Dermatofibrosarcoma protuberans of the head and neck. Am Surg 1980, 46:208-215.
41. Kamino H., Jacobson M. Dermatofibroma extending into the subcutaneous tissue. Differential diagnosis from dermatofibrosarcoma protuberans. Am J Surg Pathol 1990, 14:1156-1164.
42. Bague S., Folpe A.L. Dermatofibrosarcoma protuberans presenting as a subcutaneous mass: a clinicopathological study of 15 cases with exclusive or near-exclusive subcutaneous involvement. Am J Dermatopathol 2008, 30:327-332.
43. Zelger B., Sidoroff A., Stanzl U., et al. Deep penetrating dermatofibroma versus dermatofibrosarcoma protuberans. A clinicopathologic comparison. Am J Surg Pathol 1994, 18:677-686.
44. Bednar B. Storiform neurofibromas of the skin, pigmented and nonpigmented. Cancer 1957, 10:368-376.
45. Dupree W.B., Langloss J.M., Weiss S.W. Pigmented dermatofibrosarcoma protuberans (Bednar tumor). A pathologic, ultrastructural, and immunohistochemical study. Am J Surg Pathol 1985, 9:630-639.
46. Kaburagi Y., Hatta N., Kawara S., et al. Pigmented dermatofibrosarcoma protuberans (Bednár tumor) occurring in a Japanese infant. Dermatology 1998, 197:48-51.
47. Fletcher C.D. Giant cell fibroblastoma of soft tissue: a clinicopathological and immunohistochemical study. Histopathology 1988, 13:499-508.
48. Suehara Y., Yazawa Y., Hitachi K. Metastatic Bednar tumor (pigmented dermatofibrosarcoma protuberans) with fibrosarcomatous change: a case report. J Orthop Sci 2004, 9:662-665.
49. Rytina E.R., Ball R.Y. Transformation of recurrent dermatofibrosarcoma protuberans to its pigmented variant (Bednar tumour). Histopathology 1998, 32:384-385.
50. Zámecník M., Michal M. Giant-cell fibroblastoma with pigmented dermatofibrosarcoma protuberans component. Am J Surg Pathol 1994, 18:736-740.
51. Kini H., Raghuveer C.V., Pai M.R., et al. Fibrosarcomatous Bednar tumor with distant metastases-a case report. Indian J Pathol Microbiol 2004, 47:26-29.
52. Bisceglia M., Vairo M., Calonje E., et al. Pigmented fibrosarcomatous dermatofibrosarcoma protuberans (Bednar tumor). 3 case reports, analogy with the "conventional" type and review of the literature]. Pathologica 1997, 89:264-273.
53. Kobayashi T., Hasegawa Y., Konohana A., et al. A case of Bednar tumor. Immunohistochemical positivity for CD34. Dermatology 1997, 195:57-59.
54. Goncharuk V., Mulvaney M., Carlson J.A. Bednár tumor associated with dermal melanocytosis: melanocytic colonization or neuroectodermal multidirectional differentiation?. J Cutan Pathol 2003, 30:147-151.
55. Shmookler B.M., Enzinger F.M. Giant cell fibroblastoma: a peculiar childhood tumor. Lab Invest 1982, 46:76A.
56. Shmookler B.M., Enzinger F.M., Weiss S.W. Giant cell fibroblastoma. A juvenile form of dermatofibrosarcoma protuberans. Cancer 1989, 64:2154-2161.
57. Jha P., Moosavi C., Fanburg-Smith J.C. Giant cell fibroblastoma: an update and addition of 86 new cases from the Armed Forces Institute of Pathology, in honor of Dr. Franz M. Enzinger. Ann Diagn Pathol 2007, 11:81-88.
58. Maeda T., Hirose T., Furuya K., et al. Giant cell fibroblastoma associated with dermatofibrosarcoma protuberans: a case report. Mod Pathol 1998, 11:491-495.
59. Michal M., Zámecník M. Ultrastructure of composite tumours consisting of giant cell fibroblastoma and dermatofibrosarcoma protuberans. Zentralbl Pathol 1995, 140:415-420.
60. Pinto A., Hwang W.S., Wong A.L., et al. Giant cell fibroblastoma in childhood immunohistochemical and ultrastructural study. Mod Pathol 1992, 5:639-642.
61. Beham A., Fletcher C.D. Dermatofibrosarcoma protuberans with areas resembling giant cell fibroblastoma: report of two cases. Histopathology 1990, 17:165-167.
62. Michal M., Zamecnik M. Giant cell fibroblastoma with a dermatofibrosarcoma protuberans component. Am J Dermatopathol 1992, 14:549-552.
63. Allen P.W., Zwi J. Giant cell fibroblastoma transforming into dermatofibrosarcoma protuberans. Am J Surg Pathol 1992, 16:1127-1129.
64. Coyne J., Kaftan S.M., Craig R.D. Dermatofibrosarcoma protuberans recurring as a giant cell fibroblastoma. Histopathology 1992, 21:184-187.
65. De Chadarévian J.P., Coppola D., Billmire D.F. Bednar tumor pattern in recurring giant cell fibroblastoma. Am J Clin Pathol 1993, 100:164-166.
66. Zelger B.W., Ofner D., Zelger B.G. Atrophic variants of dermatofibroma and dermatofibrosarcoma protuberans. Histopathology 1995, 26:519-527.
67. Marini M., Saponaro A., Magariños G., et al. Congenital atrophic dermatofibrosarcoma protuberans. Int J Dermatol 2001, 40:448-450.
68. See A.C., Kossard S.S., Murrell D.F. Guess what. Dermatofibrosarcoma protuberans presenting as an atrophic red plaque. Eur J Dermatol 2001, 11:147-149.
69. Davis D.A., Sánchez R.L. Atrophic and plaquelike dermatofibrosarcoma protuberans. Am J Dermatopathol 1998, 20:498-501.
70. Fujimoto M., Kikuchi K., Okochi H., et al. Atrophic dermatofibrosarcoma protuberans: a case report and review of the literature. Dermatology 1998, 196:422-424.
71. Ashack R.J., Tejada E., Parker C., et al. A localized atrophic plaque on the back. Dermatofibrosarcoma protuberans (DFSP) (atrophic variant). Arch Dermatol 1992, 128:549. 552.
72. Page E.H., Assaad D.M. Atrophic dermatofibroma and dermatofibrosarcoma protuberans. J Am Acad Dermatol 1987, 17:947-950.
73. Chuan M.T., Tsai T.F., Wu M.C., et al. Atrophic pigmented dermatofibrosarcoma presenting as infraorbital hyperpigmentation. Dermatology 1997, 194:65-67.
74. Llombart B., Sanmartin O., Requena C., et al. Atrophic dermatofibrosarcoma protuberans with the fusion gene COL1A1-PDGFB. J Eur Acad Dermatol Venereol 2008, 22:371-374.
75. Young C.R., Albertini M.J. Atrophic dermatofibrosarcoma protuberans: case report, review, and proposed molecular mechanisms. J Am Acad Dermatol 2003, 49:761-764.
76. Barr FJ, Golitz LE, Siongco A: Sclerotic dermatofibrosarcoma protuberans-a lesion which may confused with sclerotic fibroma [abstract]. In: 31th Annual Meeting American Society of Dermatopathology; March 1997.
77. Díaz-Cascajo C., Weyers W., Borghi S. Sclerosing dermatofibrosarcoma protuberans. J Cutan Pathol 1998, 25:440-444.
78. Hattori H. Nodular sclerotic change in dermatofibrosarcoma protuberans: a potential diagnostic problem. Br J Dermatol 2003, 148:357-360.
79. Sabater-Marco V., Pérez-Vallés A., Berzal-Cantalejo F., et al. Sclerosing dermatofibrosarcoma protuberans (DFSP): an unusual variant with focus on the histopathologic differential diagnosis. Int J Dermatol 2006, 45:59-62.
80. Llatjós R., Fernández-Figueras M.T., Díaz-Cascajo C., et al. Palisading and verocay body-prominent dermatofibrosarcoma protuberans: a report of three cases. Histopathology 2000, 37:452-455.
81. Banerjee S.S., Harris M., Eyden B.P., et al. Granular cell variant of dermatofibrosarcoma protuberans. Histopathology 1990, 17:375-378.
82. Maire G., Pédeutour F., Coindre J.M. COL1A1-PDGFB gene fusion demonstrates a common histogenetic origin for dermatofibrosarcoma protuberans and its granular cell variant. Am J Surg Pathol 2002, 26:932-937.
83. Mentzel T., Beham A., Katenkamp D., et al. Fibrosarcomatous ("high-grade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol 1998, 22:576-587.
84. Goldblum J.R. CD34 positivity in fibrosarcomas which arise in dermatofibrosarcoma protuberans. Arch Pathol Lab Med 1995, 119:238-241.
85. Diaz-Cascajo C., Weyers W., Borrego L., et al. Dermatofibrosarcoma protuberans with fibrosarcomatous areas: a clinico-pathologic and immunohistochemic study in four cases. Am J Dermatopathol 1997, 19:562-567.
86. Bowne W.B., Antonescu C.R., Leung D.H., et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer 2000, 88:2711-2720.
87. Wrotnowski U., Cooper P.H., Shmookler B.M. Fibrosarcomatous change in dermatofibrosarcoma protuberans. Am J Surg Pathol 1988, 12:287-293.
88. Connelly J.H., Evans H.L. Dermatofibrosarcoma protuberans. A clinicopathologic review with emphasis on fibrosarcomatous areas. Am J Surg Pathol 1992, 16:921-925.
89. Llombart B., Monteagudo C., Sanmartín O., et al. Dermatofibrosarcoma protuberans: a clinicopathological, immunohistochemical, genetic (COL1A1-PDGFB), and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors. J Am Acad Dermatol 2011, 65:564-575.
90. Abbott J.J., Oliveira A.M., Nascimento A.G. The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans. Am J Surg Pathol 2006, 30:436-443.
91. Goldblum J.R., Reith J.D., Weiss S.W. Sarcomas arising in dermatofibrosarcoma protuberans: a reappraisal of biologic behavior in eighteen cases treated by wide local excision with extended clinical follow up. Am J Surg Pathol 2000, 24:1125-1130.
92. Sanz-Trelles A., Ayala-Carbonero A., Rodrigo-Fernández I., et al. Leiomyomatous nodules and bundles of vascular origin in the fibrosarcomatous variant of dermatofibrosarcoma protuberans. J Cutan Pathol 1998, 25:44-49.
93. Hisaoka M., Okamoto S., Morimitsu Y., et al. Dermatofibrosarcoma protuberans with fibrosarcomatous areas. Molecular abnormalities of the p53 pathway in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Virchows Arch 1998, 433:323-329.
94. Sasaki M., Ishida T., Horiuchi H., et al. Dermatofibrosarcoma protuberans: an analysis of proliferative activity, DNA flow cytometry and p53 overexpression with emphasis on its progression. Pathol Int 1999, 49:799-806.
95. Takahira T., Oda Y., Tamiya S., et al. Microsatellite instability and p53 mutation associated with tumor progression in dermatofibrosarcoma protuberans. Hum Pathol 2004, 35:240-245.
96. Orlandi A., Bianchi L., Spagnoli L.G. Myxoid dermatofibrosarcoma protuberans: morphological, ultrastructural and immunohistochemical features. J Cutan Pathol 1998, 25:386-393.
97. Sato N., Kimura K., Tomita Y. Recurrent dermatofibrosarcoma protuberans with myxoid and fibrosarcomatous changes paralleled by loss of CD34 expression. J Dermatol 1995, 22:665-672.
98. Zámecnik M., Michal M. Myxoid variant of dermatofibrosarcoma protuberans with fibrosarcomatous areas. Zentralbl Pathol 1993, 139:373-376.
99. Mentzel T., Schärer L., Kazakov D.V., et al. Myxoid dermatofibrosarcoma protuberans: clinicopathologic, immunohistochemical, and molecular analysis of eight cases. Am J Dermatopathol 2007, 29:443-448.
100. Reimann J.D., Fletcher C.D. Myxoid dermatofibrosarcoma protuberans: a rare variant analyzed in a series of 23 cases. Am J Surg Pathol 2007, 31:1371-1377.
101. Calonje E., Fletcher C.D. Myoid differentiation in dermatofibrosarcoma protuberans and its fibrosarcomatous variant: clinicopathologic analysis of 5 cases. J Cutan Pathol 1996, 23:30-36.
102. Diaz-Cascajo C. Myoid differentiation in dermatofibrosarcoma protuberans and its fibrosarcomatous variant. J Cutan Pathol 1997, 24:197-198.
103. Fisher C. Low-grade sarcomas with CD34-positive fibroblasts and low-grade myofibroblastic sarcomas. Ultrastruct Pathol 2004, 28:291-305.
104. Tardío J.C. CD34-reactive tumors of the skin. An updated review of an ever-growing list of lesions. J Cutan Pathol 2008, 35:1079-1092.
105. Hanft V.N., Shea C.R., McNutt N.S., et al. Expression of CD34 in sclerotic ("plywood") fibromas. Am J Dermatopathol 2000, 22:17-21.
106. McNiff J.M., Subtil A., Cowper S.E., et al. Cellular digital fibromas: distinctive CD34-positive lesions that may mimic dermatofibrosarcoma protuberans. J Cutan Pathol 2005, 32:413-418.
107. Diwan A.H., Horenstein M.G. Dermatofibrosarcoma protuberans association with nuchal-type fibroma. J Cutan Pathol 2004, 31:62-66.
108. Tardío J.C., Butrón M., Martín-Fragueiro L.M. Superficial acral fibromyxoma: report of 4 cases with CD10 expression and lipomatous component, two previously underrecognized features. Am J Dermatopathol 2008, 30:431-435.
109. Li N., McNiff J., Hui P., et al. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity. Am J Dermatopathol 2004, 26:267-272.
110. West R.B., Harvell J., Linn S.C., et al. Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans. Am J Surg Pathol 2004, 28:1063-1069.
111. Mori T., Misago N., Yamamoto O., et al. Expression of nestin in dermatofibrosarcoma protuberans in comparison to dermatofibroma. J Dermatol 2008, 35:419-425.
112. Cribier B., Noacco G., Peltre B., et al. Stromelysin 3 expression: a useful marker for the differential diagnosis dermatofibroma versus dermatofibrosarcoma protuberans. J Am Acad Dermatol 2002, 46:408-413.
113. Kim H.J., Lee J.Y., Kim S.H., et al. Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34. Br J Dermatol 2007, 157:319-324.
114. Bandarchi B., Ma L., Marginean C., et al. D2-40, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans. Mod Pathol 2010, 23:434-438.
115. Sachdev R., Sundram U. Expression of CD163 in dermatofibroma, cellular fibrous histiocytoma, and dermatofibrosarcoma protuberans: comparison with CD68, CD34, and factor XIIIa. J Cutan Pathol 2006, 33:353-360.
116. Pedeutour F., Coindre J.M., Nicolo G., et al. Ring chromosomes in dermatofibrosarcoma protuberans contain chromosome 17 sequences: fluorescence in situ hybridization. Cancer Genet Cytogenet 1993, 67:149.
117. Pedeutour F., Simon M.P., Minoletti F., et al. Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement. Cytogenet Cell Genet 1996, 72:171-174.
118. Simon M.P., Pedeutour F., Sirvent N., et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 1997, 15:95-98.
119. Shimizu A., O'Brien K.P., Sjöblom T., et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res 1999, 59:3719-3723.
120. Sjöblom T., Shimizu A., O'Brien K.P., et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001, 61:5778-5783.
121. Rubin B.P., Schuetze S.M., Eary J.F., et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002, 20:3586-3591.
122. McArthur G.A., Demetri G.D., van Oosterom A., et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225. J Clin Oncol 2005, 23:866-873.
123. Giacchero D., Maire G., Nuin P.A., et al. No correlation between the molecular subtype of COL1A1-PDGFB fusion gene and the clinico-histopathological features of dermatofibrosarcoma protuberans. J Invest Dermatol 2010, 130:904-907.
124. Patel K.U., Szabo S.S., Hernandez V.S., et al. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol 2008, 39:184-193.
125. Llombart B., Sanmartín O., López-Guerrero J.A., et al. Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB) study with therapeutic implications. Histopathology 2009, 54:860-872.
126. Craver R., Dewenter T., Ebran N., et al. COL1A1-PDGFB fusion in a pediatric Bednar tumor with 2 copies of a der(22)t(17;22). Cancer Genet Cytogenet 2006, 168:155-157.
127. Maire G., Fraitag S., Galmiche L., et al. A clinical, histologic, and molecular study of 9 cases of congenital dermatofibrosarcoma protuberans. Arch Dermatol 2007, 143:203-210.
128. Segura S., Salgado R., Toll A., et al. Identification of t(17;22)(q22;q13) (COL1A1/PDGFB) in dermatofibrosarcoma protuberans by fluorescence in situ hybridization in paraffin-embedded tissue microarrays. Hum Pathol 2011, 42:176-184.
129. Salgado R., Llombart B., M Pujol R., et al. Molecular diagnosis of dermatofibrosarcoma protuberans: a comparison between reverse transcriptase-polymerase chain reaction and fluorescence in situ hybridization methodologies. Genes Chromosomes Cancer 2011, 50:510-517.
130. Bianchini L., Maire G., Guillot B., et al. Complex t(5;8) involving the CSPG2 and PTK2B genes in a case of dermatofibrosarcoma protuberans without the COL1A1-PDGFB fusion. Virchows Arch 2008, 452:689-696.
131. Gloster H.M., Harris K.R., Roenigk R.K. A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996, 35:82-87.
132. Lemm D., Mügge L.O., Mentzel T., et al. Current treatment options in dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol 2009, 135:653-665.
133. DuBay D., Cimmino V., Lowe L., et al. Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer 2004, 100:1008-1016.
134. Fiore M., Miceli R., Mussi C., et al. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J Clin Oncol 2005, 23:7669-7675.
135. Paradisi A., Abeni D., Rusciani A., et al. Dermatofibrosarcoma protuberans: wide local excision vs. Mohs micrographic surgery. Cancer Treat Rev 2008, 34:728-736.
136. Arnaud E.J., Perrault M., Revol M., et al. Surgical treatment of dermatofibrosarcoma protuberans. Plast Reconstr Surg 1997, 100:884-895.
137. Ratner D., Thomas C.O., Johnson T.M., et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol 1997, 37:600-613.
138. Snow S.N., Gordon E.M., Larson P.O., et al. Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. Cancer 2004, 101:28-38.
139. Love W.E., Keiler S.A., Tamburro J.E., et al. Surgical management of congenital dermatofibrosarcoma protuberans. J Am Acad Dermatol 2009, 61:1014-1023.
140. Leevers S.J., Vanhaesebroeck B., Waterfield M.D. Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol 1999, 11:219-225.
141. Maki R.G., Awan R.A., Dixon R.H., et al. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002, 100:623-626.
142. Mizutani K., Tamada Y., Hara K., et al. Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans. Br J Dermatol 2004, 151:235-237.
143. Serra-Guillen C, Llombart B, Sanmartin O, et al: Dermatofibrosacoma protubernas Actas Dermosifiliogr (in press).
144. Lemm D., Muegge L.O., Hoeffken K., et al. Remission with imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans-a case report. Oral Maxillofac Surg 2008, 12:209-213.
145. Price V.E., Fletcher J.A., Zielenska M., et al. Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans. Pediatr Blood Cancer 2005, 44:511-515.
146. Mehrany K., Swanson N.A., Heinrich M.C., et al. Dermatofibrosarcoma protuberans: a partial response to imatinib therapy. Dermatol Surg 2006, 32:456-459.
147. Savoia P., Ortoncelli M., Quaglino P., et al. Imatinib mesylate in the treatment of a large unresectable dermatofibrosarcoma protuberans: a case study. Dermatol Surg 2006, 32:1097-1102.
148. Wright T.I., Petersen J.E. Treatment of recurrent dermatofibrosarcoma protuberans with imatinib mesylate, followed by Mohs micrographic surgery. Dermatol Surg 2007, 33:741-744.
149. Heinrich M.C., Joensuu H., Demetri G.D., et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 2008, 14:2717-2725.
150. Thomison J., McCarter M., McClain D., et al. Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate. J Cutan Pathol 2008, 35:1003-1006.
151. Han A., Chen E.H., Niedt G., et al. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans. Arch Dermatol 2009, 145:792-796.
152. Rutkowski P., Van Glabbeke M., Rankin C.J., et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010, 28:1772-1779.
153. Gooskens S.L., Oranje A.P., van Adrichem L.N., et al. Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP). Pediatr Blood Cancer 2010, 55:369-373.
154. Kérob D., Porcher R., Vérola O., et al. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Clin Cancer Res 2010, 16:3288-3295.
155. Edelweiss M., Malpica A. Dermatofibrosarcoma protuberans of the vulva: a clinicopathologic and immunohistochemical study of 13 cases. Am J Surg Pathol 2010, 34:393-400.
156. Stacchiotti S., Pedeutour F., Negri T., et al. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib. Int J Cancer 2011, 129:1761-1772.
157. Rutkowski P., Wozniak A., Switaj T. Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans. Sarcoma 2011, 2011:959132.
158. Liu Y.C., Chen S.C., Chang C., et al. Platelet-derived growth factor is an autocrine stimulator for the growth and survival of human esophageal carcinoma cell lines. Exp Cell Res 1996, 228:206-211.
159. Funa K., Ahgren A. Characterization of platelet-derived growth factor (PDGF) action on a mouse neuroblastoma cell line, NB41, by introduction of an antisense PDGF beta-receptor RNA. Cell Growth Differ 1997, 8:861-869.
160. Greco A., Roccato E., Miranda C., et al. Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement. Int J Cancer 2001, 92:354-360.
161. Suit H., Spiro I., Mankin H.J., et al. Radiation in management of patients with dermatofibrosarcoma protuberans. J Clin Oncol 1996, 14:2365-2369.
162. Ballo M.T., Zagars G.K., Pisters P., et al. The role of radiation therapy in the management of dermatofibrosarcoma protuberans. Int J Radiat Oncol Biol Phys 1998, 40:823-827.
163. Sun L.M., Wang C.J., Huang C.C., et al. Dermatofibrosarcoma protuberans: treatment results of 35 cases. Radiother Oncol 2000, 57:175-181.
164. Dagan R., Morris C.G., Zlotecki R.A., et al. Radiotherapy in the treatment of dermatofibrosarcoma protuberans. Am J Clin Oncol 2005, 28:537-539.
165. McArthur G. Dermatofibrosarcoma protuberans: recent clinical progress. Ann Surg Oncol 2007, 14:2876-2886.
166. Dermatofibrosarcoma Protuberans. Version 1 National Comprehensive Cancer Network Clinical practice guidelines in oncology, Accessed December 2009. http://www.nccn.org/professionals/physicians_gls/PDF/dfsp.pdf.
167. Smola M.G., Soyer H.P., Scharnagl E. Surgical treatment of dermatofibrosarcoma protuberans. A retrospective study of 20 cases with review of literature. Eur J Surg Oncol 1991, 17:447-453.
168. Gayner S.M., Lewis J.E., McCaffrey T.V. Effect of resection margins on dermatofibrosarcoma protuberans of the head and neck. Arch Otolaryngol Head Neck Surg 1997, 123:430-433.